ADPT

Rating buyAI Memo

Adaptive Biotechnologies

As of 2026-01-16/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-16 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Final Q4 & Full Year 2025 Results and Conference Call • 2026-02-28

Expected move: -16%

Biggest risk

If MRD adoption is slower than modeled, reimbursement and payer pushback persist, or the company issues dilutive financing after disappointing results, shares could revisit the single-digit range (~$8).

Invalidation

Break below $8 or thesis failure.

What would change my mind?

If MRD commercial demand accelerates, reimbursement outcomes improve, and reported results beat cautious expectations, multiple expansion plus revenue growth could lift shares toward and above $22 within 12 months.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-16

Base target

$18

p=60%

Bull target

$22

p=20%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Analyst revisions and updated guidance
MRD commercial ramp and reimbursement progress
If MRD commercial demand accelerates, reimbursement outcomes improve, and reported results beat cautious expectations, multiple expansion plus revenue growth could lift shares toward and above $22 within 12 months.

BearKey bullets

Competition and pricing pressure in diagnostics
Quarterly results below guidance leading to dilution
Reimbursement/payer pushback on MRD assays

WatchKey bullets

Final Q4 & Full Year 2025 Results and Conference Call

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $18 (p=60%)

Bull/Bear spread: +3% / -63%

Vs latest close: Bull +3% · Base -16% · Bear -63%

Scenario probabilities

Bull Target: $22 (p=20%)Base Target: $18 (p=60%)Bear Target: $8 (p=20%)

Commentary

Market commentary around the Jan 13 preliminary release has been cautiously constructive — coverage snippets show analyst averages near $18–21, indicating upside vs the anchor for many desks [#SERP-2]. News flow is focused on MRD commercial traction and upcoming final results, creating a mix of optimism and execution caution [#SERP-1].

As of 2026-01-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Analyst revisions and updated guidance
MRD commercial ramp and reimbursement progress

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-16Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$19.02

Range (USD)

$10.00 - $22.05

Count

Query: Adaptive Biotechnologies Corp Common (ADPT) analyst consensus price target high low average

Adaptive Biotechnologies Corp (ADPT) Stock Forecast & Price Target
Search result #1
According to projections from 7 analysts, the average 12-month price target for Adaptive Biotechnologies is 20, with a high estimate of 21 and a low estimate ...
Open source
Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target
Search result #2
The highest price target for ADPT is $21.00, while the lowest price target for ADPT is $10.00. The average price target represents a forecasted downside of - ...
Extracted: $21.00, $10.00Open source
Consensus Adaptive Biotechnologies Corporation - MarketScreener
Search result #3
Average target price. 19.86USD. Spread / Average Target. +24.81%. High Price Target. 21.00USD. Spread / Highest target. +31.99%. Low Price Target. 18.00USD.
Extracted: $19.86, $21.00, $18.00Open source
Adaptive Biotechnologies Corporation (ADPT) - Yahoo Finance
Search result #4
Analyst Price Targets. 18.00. 20.00 Average. 17.90 Current. 21.00 High. Analyst ... Price Target 11 -> 16. View More. Statistics: ADPT. View More. Valuation ...
Open source
Adaptive Biotechnologies (ADPT) Price Targets
Search result #5
The forecasts range from a low of $18.00 to a high of $21.00. The average price target represents an increase of 10.68% from the last closing price of $18.07.
Extracted: $18.00, $21.00, $18.07Open source
ADPT - Adaptive Biotechnologies Corporation (NasdaqGS) - Fintel
Search result #6
Price Target. The average one-year price target for Adaptive Biotechnologies Corporation is $20.25. The forecasts range from a low of $18.18 to a high of $22.05 ...
Extracted: $20.25, $18.18, $22.05Open source

Scenarios

Bull Target (Scenario probability)

$22 / p=20% prob

Base Target (Scenario probability)

$18 / p=60% prob

Bear Target (Scenario probability)

$8 / p=20% prob

Price $21 as of 2026-07-14

Nearest Scenario: Bull (∆ 3%)

Targets vs latest close: Bull +3% · Base -16% · Bear -63%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-02-28
Final Q4 & Full Year 2025 Results and Conference Call
Company published preliminary results on Jan 13, 2026 and announced it will publish final Q4/FY2025 results and host a conference call; final release + call may materially reprice shares (assumed conference call by 2026-02-28 based on IR notice) [#SERP-1].
Prob 90.00% • Move 20.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

Analyst revisions and updated guidance
2026-04-16
Consensus/street targets show a cluster near $18–21; company commentary or results could trigger near-term target revisions and repricing (using a conservative 90-day horizon) [sanity-check: analyst snippets at [#SERP-2], [#SERP-3]].
Prob 60% • Move 15% • Priced-in 50%

Long-term Catalysts

Months to a year

MRD commercial ramp and reimbursement progress
2027-01-16
Sustained adoption of MRD assays and favorable reimbursement decisions would drive durable revenue growth and margin expansion; conservative expected date set one year out to reflect multi-quarter commercial build [assumption: +365 days] [#SERP-1].
Prob 45% • Move 60% • Priced-in 25%

Risks

Competition and pricing pressure in diagnostics
Quarterly results below guidance leading to dilution
Reimbursement/payer pushback on MRD assays
Slower-than-expected MRD commercial adoption

Peers

Symbol	Summary
GH	Guardant Health — liquid biopsy / oncology diagnostics peer with similar commercialization and reimbursement dynamics.
NTRA	Natera — molecular diagnostics company exposed to adoption and payer coverage trends for oncology assays.
ILMN	Illumina — sequencing-platform peer whose market movements can affect sentiment for diagnostics/sequencing firms.
EXAS	Exact Sciences — cancer-detection commercial play; useful comparator for commercialization / sales ramp risks.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Adaptive Biotechnologies Corp Common (ADPT) analyst consensus price target high low average
Analysis date: 2026-01-16

AI Stock Memo: ADPT - Adaptive Biotechnologies - RankAlpha